1.Web Resources for Stem Cell Research
Wei TING ; Peng XING ; Ye LILI ; Wang JIAJIA ; Song FUHAI ; Bai ZHOUXIAN ; Han GUANGCHUN ; Ji FENGMIN ; Lei HONGXING
Genomics, Proteomics & Bioinformatics 2015;(1):40-45
In this short review, we have presented a brief overview on major web resources relevant to stem cell research. To facilitate more efficient use of these resources, we have provided a pre-liminary rating based on our own user experience of the overall quality for each resource. We plan to update the information on an annual basis.
2.Investigation of the application of nosocomial infection prevention and control measures as stipulated in COVID-19 pandemic emergency plans
Yang CAO ; Yinghong WU ; Xiulan CHANG ; Hui CHEN ; Liang GUO ; Jing HUANG ; Fengmin JI ; Gehong LI ; Huifang LI ; Kun LIU ; Rong LIU ; Cuiling WANG ; Hong WANG ; Yuxia WANG ; Xinbing XU ; Yanqiu YANG ; Yusong YANG ; Aihua ZHANG ; Wenyan ZHANG
Chinese Journal of Hospital Administration 2020;36(10):818-822
Objective:To learn the application of nosocomial infection prevention and control measures as stipulated in COVID-19 emergency plans by medical institutions at all levels in the region, for the purpose of strengthening epidemic prevention and control.Methods:During March 12-13, 2020, customized questionnaires were used to learn from 186 hospitals and medical institutions regarding the basics of their nosocomial prevention management departments, emergency plan application and revisions made. Comparison of the ratios or constituent ratios were tested with χ2 test, while the continuous variables analysis between groups was verified with one-way ANOVA. Results:77.53% of the medical institutions had set up independent nosocomial infection management departments, and 87.30% of the institutions were qualified. 80% of the medical institutions had in place emergency plans for respiratory infectious diseases, but 98.05% of them had revised their plans during the pandemic, with an average of 10.85 newly added and revised provisions. Only 30.11% of emergency planed provide for clearly graded early warning.Conclusions:Efforts should be upgraded to develop an emergency prevention and control system for infection prevention and control in epidemics, and improve technical support for infection prevention and control in the system; to strengthen the clearly-graded early warning and graded responses in a scientific manner; and conduct regular drills, revise plan to ensure its applicability.
3.Efficacy and safety of low-dose aspirin on preventing transplant renal artery stenosis: a prospective randomized controlled trial
Xiangyong TIAN ; Bingqing JI ; Xiaoge NIU ; Wenjing DUAN ; Xiaoqiang WU ; Guanghui CAO ; Chan ZHANG ; Jingge ZHAO ; Zhiwei WANG ; Yue GU ; Huixia CAO ; Tao QIN ; Fengmin SHAO ; Tianzhong YAN
Chinese Medical Journal 2023;136(5):541-549
Background::Transplant renal artery stenosis (TRAS) is a vascular complication after kidney transplantation associated with poor outcomes. This study aimed to analyze the efficacy and safety of low-dose aspirin for preventing TRAS.Methods::After kidney transplantation, patients were enrolled from January 2018 to December 2020 in Henan Provincial People’s Hospital. A total of 351 enrolled recipients were randomized to an aspirin group with low-dose intake of aspirin in addition to standard treatment ( n = 178), or a control group with only standard treatment ( n = 173). The patients was initially diagnosed as TRAS (id-TRAS) by Doppler ultrasound, and confirmed cases were diagnosed by DSA (c-TRAS). Results::In the aspirin and control groups, 15.7% (28/178) and 22.0% (38/173) of the recipients developed id-TRAS, respectively, with no statistical difference. However, for c-TRAS, the difference of incidence and cumulative incidence was statistically significant. The incidence of c-TRAS was lower in the aspirin group compared with the control group (2.8% [5/178] vs. 11.6% [20/173], P = 0.001). Kaplan–Meier estimates and Cox regression model identified the cumulative incidence and hazard ratio (HR) of TRAS over time in two groups, showing that recipients treated with aspirin had a significantly lower risk of c-TRAS than those who were not treated (log-rank P = 0.001, HR = 0.23, 95% confidence interval [CI]: 0.09–0.62). The levels of platelet aggregation rate ( P < 0.001), cholesterol ( P = 0.028), and low-density lipoprotein cholesterol ( P = 0.003) in the aspirin group were decreased compared with the control group in the third-month post-transplantation. For the incidence of adverse events, there was no statistical difference. Conclusion::Clinical application of low-dose aspirin after renal transplant could prevent the development of TRAS with no significant increase in adverse effects.Trial Registration::Clinicaltrials.gov, NCT04260828.